Validation of noninvasive methods for detecting hepatic steatosis in patients with human immunodeficiency virus infection

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 2, 2015, Pages 402-405

  Siddiqui, M Shadab ^a   Patidar, Kavish R ^a   Boyett, Sherry ^a   Smith, Paula G ^a   Sanyal, Arun J ^a   Sterling, Richard K ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

CI; Diagnosis; HAART; HIV; LAP; LFS; Liver Disease; NAFLD; Prognostic Factor; ROC; Test

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID ACCUMULATION PRODUCT INDEX; LIVER FAT SCORE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NON INVASIVE PROCEDURE; NONALCOHOLIC FATTY LIVER; RETROSPECTIVE STUDY; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; COHORT ANALYSIS; COMPLICATION; ECHOGRAPHY; FATTY LIVER; LIVER; MIDDLE AGED; PATHOLOGY; RECEIVER OPERATING CHARACTERISTIC; VALIDATION STUDY;

ADULT; COHORT STUDIES; FATTY LIVER; FEMALE; HIV INFECTIONS; HUMANS; LIPID ACCUMULATION PRODUCT; LIVER; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 84927698587     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.06.027     Document Type: Article

References (13)

1. Weber R., Ruppik M., Rickenbach M., et al. Decreasing mortality and changing patterns of causes of death in the Swiss HIV cohort study. HIV Med 2013, 14:195-207.
2. Weber R., Sabin C.A., Friis-Moller N., et al. Liver-related deaths in persons infected with the human immunodeficiency virus: The D:A:D study. Arch Intern Med 2006, 166:1632-1641.
3. Vallet-Pichard A., Mallet V., Pol S. Nonalcoholic fatty liver disease and HIV infection. Semin Liver Dis 2012, 32:158-166.
4. Chitturi S., Abeygunasekera S., Farrell G.C., et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002, 35:373-379.
5. Kalra S., Agrawal N. Diabetes and HIV: current understanding and future perspectives. Curr Diab Rep 2013, 13:419-427.
6. Guaraldi G., Squillace N., Stentarelli C., et al. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Clin Infect Dis 2008, 47:250-257.
7. Ingiliz P., Valantin M.A., Duvivier C., et al. Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. Hepatology 2009, 49:436-442.
8. Smith J.O., Sterling R.K. Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis C. Aliment Pharmacol Ther 2009, 30:557-576.
9. Shah A.G., Smith P.G., Sterling R.K. Comparison of FIB-4 and APRI in HIV-HCV coinfected patients with normal and elevated ALT. Dig Dis Sci 2011, 56:3038-3044.
10. Kotronen A., Peltonen M., Hakkarainen A., et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology 2009, 137:865-872.
11. Bedogni G., Kahn H.S., Bellentani S., et al. Asimple index of lipid overaccumulation is a good marker of liver steatosis. BMC Gastroenterol 2010, 10:98.
12. Sterling R.K., Smith P.G., Brunt E.M. Hepatic steatosis in human immunodeficiency virus. JClin Gastroenterol 2013, 47:182-187.
13. Prati D., Taioli E., Zanella A., et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002, 137:1-10.